Pages
Products
Adalimumab Stable Cell Line - CHO-K1

Adalimumab Stable Cell Line - CHO-K1

Cat.No. :  CSC-BS0006 Host Cell:  CHO-K1

Inquire for Price

Cell Line Information

Safety and Packaging

Cat. No. CSC-BS0006
Description This cell line is engineered to stably produce Adalimumab which is a monoclonal antibody against human TNF.
Biosimilar Adalimumab
Host Cell CHO-K1
Host Cell Species Cricetulus griseus (Chinese hamster)
Stability Validated for at least 10 passages
Application

1. Biosimilar Development

2. Large-Scale Biomanufacturing

3. Preclinical Research

4. Drug Development and Testing

Growth Conditions 37° C, 5% CO2
Quality Control Negative for bacteria, yeast, fungi and mycoplasma.
Shipping Dry ice
Storage Liquid nitrogen
Mycoplasma Negative
Format One frozen vial containing millions of cells
Storage Liquid nitrogen
Safety Considerations

The following safety precautions should be observed.

1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum.

2. No eating, drinking or smoking while handling the stable line.

3. Wash hands after handling the stable line and before leaving the lab.

4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells.

5. All waste should be considered hazardous.

6. Dispose of all liquid waste after each experiment and treat with bleach.

Ship Dry ice
Quick Inquiry

Publications

Q & A

Customer Reviews

Customer Q&As
What is Adalimumab?

A: Adalimumab is a disease-modifying antirheumatic drug (DMARD) and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).

What is the mechanism of action of Adalimumab?

A: Adalimumab works by selectively binding to a protein called tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, adalimumab inhibits its activity and reduces inflammation.

What type of cancer is Adalimumab used for?

A: Pembrolizumab has shown promising results in treating many types of cancer, including melanoma, non-small cell lung cancer, and bladder cancer.

Is Adalimumab a PD-1 TNF-α?

A: Yes. Adalimumab is a specific inhibitor of TNF-α, and does not affect other cytokines or immune cells. This makes it a targeted therapy with fewer side effects compared to non-specific immunosuppressive drugs that affect multiple pathways.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Great!

Great! To produce a therapeutic dose of Adalimumab, a stable cell line is needed.

United States

02/23/2023

Save time

The adalimumab stable cells are grown in suspension culture, which not only simplifies the purification process but also reduces the risk of contamination. I recommend it.

United States

04/11/2023

Effective

The stable cell line that produces functional pembrolizumab using CHO-K1 cells is a significant step forward in the fight against cancer. This helps a lot with my project.

Germany

08/09/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction